Leaflet ROBINUL 0.2mg / ml solution for injection


Indicated for: asthma; chronic obstructive pulmonary disease

Substance: glycopyrronium bromide (bronchodilator)

ATC: A03AB02 (Alimentary tract and metabolism | Drugs for functional gastrointestinal disorders | Synthetic anticholinergics, quaternary ammonium compounds)

Glycopyrronium bromide is an anticholinergic medication primarily used for the treatment of obstructive respiratory diseases, such as chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors in the airways, leading to relaxation of bronchial smooth muscles and airway dilation, making breathing easier.

It is indicated for:

- Maintenance treatment of COPD to relieve symptoms such as shortness of breath.
- Reducing the frequency of disease exacerbations.

Glycopyrronium bromide is administered via an inhaler, usually once daily, as directed by a doctor.

Side effects may include dry mouth, throat irritation, cough, constipation, headache, or, rarely, allergic reactions. It is contraindicated in patients with hypersensitivity to glycopyrronium or other anticholinergics and should be used with caution in those with narrow-angle glaucoma, urinary retention, or other conditions that may be worsened by anticholinergic effects.

General data about ROBINUL 0.2mg / ml

  • Substance: glycopyrronium bromide
  • Date of last drug list: 01-01-2026
  • Commercial code: W69323001
  • Concentration: 0.2mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: KERN PHARMA, S.L. - SPANIA
  • Holder: CN UNIFARM S.A. - ROMANIA
  • Number: 768/2022/01
  • Shelf life: 3 years

Pharmaceutical forms available for glycopyrronium bromide

Concentrations available for glycopyrronium bromide

  • 0.2mg/ml
  • 2.2mg/dose
  • 320mcg/ml
  • 44mcg